von Eyben, F. E., Singh, A., Zhang, J., Nipsch, K., Meyrick, D., Lenzo, N., . . . Baum, R. P. (2019). (177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget.
Style de citation Chicagovon Eyben, Finn Edler, et al. "(177)Lu-PSMA Radioligand Therapy of Predominant Lymph Node Metastatic Prostate Cancer." Oncotarget 2019.
Style de citation MLAvon Eyben, Finn Edler, et al. "(177)Lu-PSMA Radioligand Therapy of Predominant Lymph Node Metastatic Prostate Cancer." Oncotarget 2019.
Attention : ces citations peuvent ne pas être correctes à 100%.